MAPK7 and lung adenocarcinoma: To assess the relevance of the combined inhibition of FAK and ERK5 in a model of lung adenocarcinoma in vivo, we treated the KP mice 12 weeks after Cre induction with the FAK inhibitor, VS-4718 either alone (FAKi) or in combination with the ERK5 inhibitor, XMD8-92 (FAKi + ERK5i) for 2 weeks (Fig. 6A).